Changes in at-home sleep electroencephalography (EEG) may serve as an early biomarker of neurodegeneration associated with Alzheimer disease (AD), suggests a study published in Alzheimer’s & Dementia.
Changes in at-home sleep electroencephalography (EEG) may serve as an early biomarker of neurodegeneration associated with Alzheimer disease (AD), suggests a study published in Alzheimer’s & Dementia.
Dysphagia, gastroparesis, constipation, and IBS without diarrhea appear to increase the risk of a subsequent diagnosis of idiopathic Parkinson disease, according to a study published online ahead of print in the journal Gut.
Dysphagia, gastroparesis, constipation, and IBS without diarrhea appear to increase the risk of a subsequent diagnosis of idiopathic Parkinson disease, according to a study published online ahead of print in the journal Gut.
Use of prescription proton pump inhibitors that stretched 4.5 years or longer was associated with an increased risk of dementia, according to study findings published online ahead of print in Neurology.
Use of prescription proton pump inhibitors that stretched 4.5 years or longer was associated with an increased risk of dementia, according to study findings published online ahead of print in Neurology.
Approximately 40% of people with a post-viral syndrome resembling long COVID, but without a test result confirming SARS-CoV-2 infection, showed evidence of an immune response to SARS-CoV-2 infection, according to study findings published...
Approximately 40% of people with a post-viral syndrome resembling long COVID, but without a test result confirming SARS-CoV-2 infection, showed evidence of an immune response to SARS-CoV-2 infection, according to study findings published...
Anxious individuals rely less on the dorsolateral prefrontal cortex (FPl) for controlling emotional actions, according to a recent study published in Nature Communications.
Anxious individuals rely less on the dorsolateral prefrontal cortex (FPl) for controlling emotional actions, according to a recent study published in Nature Communications.
A first-in-humans trial undertaken by Cleveland Clinic researchers has shown that using deep brain stimulation (DBS) to target the dentate nucleus of the cerebellum may help post-stroke rehabilitation patients recover from motor impairment.
A first-in-humans trial undertaken by Cleveland Clinic researchers has shown that using deep brain stimulation (DBS) to target the dentate nucleus of the cerebellum may help post-stroke rehabilitation patients recover from motor impairment.
For individuals with radiologically isolated syndrome (RIS), early intervention with teriflunomide may prevent the time to development of multiple sclerosis (MS) by as much as 63%.
For individuals with radiologically isolated syndrome (RIS), early intervention with teriflunomide may prevent the time to development of multiple sclerosis (MS) by as much as 63%.
Just 3 months of home-based transcutaneous electrical stimulation improved obstructive sleep apnea (OSA) severity and sleepiness in patients with low adherence to continuous positive airway pressure (CPAP) therapy.
Just 3 months of home-based transcutaneous electrical stimulation improved obstructive sleep apnea (OSA) severity and sleepiness in patients with low adherence to continuous positive airway pressure (CPAP) therapy.
The cerebellum contributes to generalized convulsive seizures by altering the activity of a specific group of neurons in the midbrain that subsequently initiates the seizures, new study results suggest.
The cerebellum contributes to generalized convulsive seizures by altering the activity of a specific group of neurons in the midbrain that subsequently initiates the seizures, new study results suggest.
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click